Home » Uncategorized » March 14 — SABPA Sci & Tech Symposium: “Immunotherapy, the New Frontier of Disease Treatment”

March 14 — SABPA Sci & Tech Symposium: “Immunotherapy, the New Frontier of Disease Treatment”

posted in: Uncategorized | 0

SABPA is holding the annual Sci & Tech Symposium. The theme of this year is “Immunotherapy, the New Frontier of Disease Treatment” .

Immunotherapy including allergy, diabetes and cancer immunotherapy has been studied for decades, but only recently has it received much attention, especially in oncology area of research. It was the central topic at recent 2014 AACR (American Association for Cancer Research) and ASCO (American Society of Clinical Oncology) annual meetings. With recent FDA approval of immunotherapy agents from Merck and Bristol-Myers for the treatment of cancer, and with much more under development and clinical trials globally, immunotherapy could be the game-changing treatment with its potential to cure certain types of cancer. Many pharmaceutical companies have renewed their strong interests and invested greatly in immunotherapy for multiple disease areas either internally or through external collaborations.

This year’s SABPA Science & Technology Forum XIII will focus on current frontiers in immunotherapy. It will bring academic and industry leaders in the immunotherapy field from San Diego and its neighboring area to address opportunities and challenges of immunotherapy in many disease areas, particularly in cancer.

 

When: March 14, 2015 from 8:30am-1pm

Where: UCSD’s Institute of Americas

(Directions available here)

 

Register at: https://www.123signup.com/register?id=yppvf

$20 for online registration

$10 for students and post-docs

$40 for on-site registration

Online registration ends March 11, 2015

 

Speakers

8:40 – 9:15

Jonathan Benjamin, M.D.

Medical Director, Amgen

9:15 – 9:45

Greg Daniels, M.D

Medical Oncologist, UCSD Thornton Hospital and UCSD Medical Center

9:45 – 10:15

Michael Cooke, Ph.D.

Director of Immunology, Genomics Institute of the Novartis Research Foundation

10:45 – 11:15

Matthias von Herrath, M.D.

Director of the Center for Type 1 Diabetes Research, La Jolla Institute of Allergy and Immunology

11:15 – 11:45

Andreas Niethammer, M.D., Ph.D.

Vice president of Clinical product development at Tocagen

11:45 – 12:45

Panel Discussion

Lewis R. Vann, Ph.D. (Moderator)

Sr. Manager, In Vivo Pharmacology & Clinical Lab Services, The Jackson Laboratory

Jonathan Benjamin, M.D.

Medical Director, Amgen

Enchi Liu Ph.D.

Senior Director, Clinical Development at Janssen

David Miao, Ph.D.

CSO, Concortis Biosystems Corp.

Matthias von Herrath, M.D.

Director of the Center for Type 1 Diabetes Research, La Jolla Institute of Allergy and Immunology

Leave a Reply